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Dear Editor,
Over the past decade, next-generation sequencing (NGS) has
become a useful tool to identify novel or emerging infectious
agents.1 Although NGS is not yet used as a routine diagnostic tool,
it is increasingly used as a second line of investigation for select clinical
cases, particularly when routine molecular and serological assays fail to
identify a causative pathogen. We developed a NGS-based pipeline
(ezVIR) to process NGS data for the identiﬁcation of viruses in
humans2 with the aim of identifying divergent or unexpected viruses
in biological specimens of subjects with unexplained clinical
syndromes.2,3
We used ezVIR to analyze 30 nasopharyngeal swab specimens
collected in a previous study that examined the causes of fever in
Tanzanian children4 who were suffering from respiratory symp-
toms of any type but for whom an infectious agent was not detected
(except colonizing bacteria in the nasopharynx) despite extensive
investigations, including viral, bacterial and parasitic molecular and
serological assays.4 The specimens were pooled in groups of ﬁve
and assessed according to the speciﬁc RNA and DNA library
preparation protocols as previously described2 for NGS analysis
(paired-end sequencing using the 100-bp protocol with indexing on
a HiSeq 2500 (Illumina, San Diego, CA, USA). Unexpectedly, an
astrovirus VA1 was identiﬁed in pool 1 (Figure 1; Supplementary
Table S1).
Each specimen in pool 1 (patients T32, T794, T359, T560
and T524) was analyzed individually using the astrovirus
VA1-speciﬁc real-time reverse-transcription polymerase chain
reaction (RT-PCR) targeting the capsid region (forward primer
5′-CCA TCA GCA GTT ACY GGG TCT GT-3′; reverse primer
5′-CGT GGC TCC AGG TGA YTG T-3′; probe 5′-FAM-TTT CCG
CAT ATC CC-MGB_NFQ-3′) under the following cycling conditions:
50 °C for 30 min; 95 °C for 15 min; 45 cycles of 15 s at 94 °C and
1 min at 55 °C. Patient T359 was conﬁrmed positive for astrovirus
VA1 (Ct value= 29.6; Figure 1). The initial T359 nasopharyngeal
specimen was reanalyzed individually by NGS. NGS data were
analyzed with ezVIR and completed by performing a de novo
analysis. As shown in the ezVIR phase 2 report, 91.5% coverage of
the astrovirus VA1 genome was obtained (305 mapped reads), with
a maximum coverage depth of 11-fold. Phylogenetic analysis of the
capsid fragment consensus sequence (1077 nucleotides long)
obtained from de novo assembly5 shows the closest nucleotide
homology (97.8%; Figure 1) with the novel human astrovirus
(HAstV) VA1/HMO-C-UK1 sequence (KM358468, corresponding to
nucleotides 5137− 6213). The presence of a parainﬂuenza virus type 4
(PIV-4) was also detected in the ezVIR phase 2 report, with lower
signals for both parameters (174 mapped reads, 38.5% genome
coverage, maximum coverage depth of sevenfold). However, using
the FTD Respiratory pathogens 21 commercial assay (Fast-track
Diagnostics, Sliema, Malta), the PIV-4 genome was not detected in
the specimen, suggesting a viral load below the limit of detection of
this assay (the limit of positivity was Ct values ⩽ 37).
By contrast, in agreement with the ezVIR phase 2 report for pool 1
(Figure 1), patients T32 and T794 were conﬁrmed positive for PIV-2
(Ct value= 21.6) and PIV-4 (Ct value = 31), respectively, by speciﬁc
real-time RT-PCR. This ﬁnding suggests that the PIV-4-negative result
in patient T359 reﬂects a very low viral load rather than potential
mismatches between the assay target and the viral genome sequences
of some PIV-4 circulating in this speciﬁc area during the study. For
this reason, PIV-4 is considered unlikely to be responsible for the
respiratory symptoms in this patient. Furthermore, an intrinsic
consequence of highly sensitive NGS technology is the increased
detection of interspecimen contamination. Therefore, the presence of
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several thousands of PIV-4 mapped reads in pool 1 and pools 4, 5 and
6 allows the possibility of potential contamination from neighboring
PIV-4-positive samples.
Patient T359 was a 13-month-old girl brought to the Amana
District Hospital in Dar es Salaam, Tanzania, in June 2008 for fever
(39.3 °C), runny nose and cough for the past three days. She had no
other symptoms, in particular no diarrhea, abdominal pain, vomiting
or rash. Except for the elevated temperature, the patient’s vital signs
were normal (the respiratory rate was 35 breaths/min), there was no
sign of severe sepsis or respiratory distress, and the detailed physical
examination did not reveal any abnormality. The caregivers responded
negatively to questions about the presence of acute disease in contact
persons or chronic disease in the child. The leukocyte count
(leukocytes 33× 109/L with a neutrophilic predominance), C-reactive
protein (139.1 mg/mL) and procalcitonin levels (5.772 µg/L) were
elevated. Other blood tests were within the normal range (hemoglobin
9.7 g/dL, alanine transaminase 43 U/L, hematocrit 29.1% and platelets
453× 109/L). The urine dipstick was positive for leukocytes, and thus
the patient was treated with cotrimoxazole, but the urine culture was
sterile. As mentioned, no viral, bacterial or parasitic agent was
evidenced after a broad range of investigations, including blood
culture. In particular, virological screening included the following
speciﬁc real-time RT-PCR assays: inﬂuenza A and B; respiratory
syncytial virus; metapneumovirus; PIV types 1 and 3; rhinovirus;
enterovirus; coronavirus (HKU1, NL63, 229E and OC43); bocavirus;
adenovirus; human herpesvirus 6; parvovirus B19; dengue;
chikungunya; West Nile and Rift Valley viruses. She was also screened
for antigen detection of adenovirus and rotavirus, and serological
assays targeting IgM for Epstein−Barr virus, cytomegalovirus, hepa-
titis A and E, mumps and measles were performed. The clinical
diagnosis retained was a tracheobronchitis of unknown etiology.
Astrovirus VA1 belongs to the novel Mamastrovirus 9 species
(Astroviridae family) and was ﬁrst identiﬁed in 2009 in human stools
during an outbreak of acute gastroenteritis.6–8 Its prevalence in stools
ranges from 0.2% to 1.6% in diarrheic and non-diarrheic subjects
worldwide.8–10 Furthermore, astrovirus VA1 has been identiﬁed in brain
biopsies of immunocompromised patients with central nervous system
disease,9,11–13 but it has never been documented in respiratory speci-
mens until now. Current molecular diagnostic assays used in most
routine laboratories target only the classical HAstV 1–8 serotypes, which
belong to the Mamastrovirus 1 species; yet, astrovirus VA1 cannot be
diagnosed because it shares only a 46% nucleotide sequence identity
with the full genome of HAstV-1. This is particularly unfortunate, as a
recent investigation of healthy adult blood donors in the United States
showed that 65% of the samples were seropositive.14 In terms of public
health relevance, there is increasing evidence that astrovirus VA1 and
other novel HAstVs recently described worldwide (i.e., astrovirus VA1-5
and MLB1-315) may be of importance in routine diagnostics, particu-
larly in immunocompromised patients. To our knowledge, our ﬁnding
is the ﬁrst documented case of an astrovirus VA1 in the respiratory
tract, and it justiﬁes considering the potential association of recently
identiﬁed new human astroviruses, such as astrovirus VA1, with
Figure 1 Specimen analysis ﬂowchart. NGS analyses are in purple. Astrovirus VA1 and PIV-4-speciﬁc real-time RT-PCR screenings are in orange and blue,
respectively. The phylogenetic analysis is based on a 1077-nucleotide-long fragment that maps to the capsid region (nucleotides 5137 to 6213 of VA1/HMO-
C-UK1 (KM358468)). Abbreviations: cycle threshold, Ct; next-generation sequencing, NGS; parainﬂuenza virus type-4, PIV-4.
Astrovirus VA1 identiﬁcation in a febrile child
S Cordey et al
2
Emerging Microbes & Infections
respiratory diseases of unknown origin. Large prospective prevalence
investigations are needed for a better understanding of the epidemio-
logical and clinical relevance of novel astroviruses.
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